A vaccine that either prevents infections with cancer-causing viruses—e.g., HPV—treats existing cancer or prevents the development of cancer in certain high risk individuals. The first effective cancer vaccine is that for preventing cervical cancer. Dendreon Corp’s Provenge, a vaccine for advanced prostate cancer, was approved by the FDA in 2010 and adds about 4 months of life to the average person’s lifespan, at an estimated cost of $100,000. Other CV candidates include peptides, proteins, whole cancer cells, dendritic cells, gangliosides, heat-shock proteins, viral and bacterial vectors, and oligonucleotides

Mentioned in

References in periodicals archive

They were there in our house to inquire if we have knowledge when their teen girls will be given their second dose of the anti-cervical cancer vaccine.

Rough Cuts: When is the second dose schedule?

for its lead product candidate eftilagimod alpha as part of a cancer vaccine. The agreements enable the two parties to collaborate on clinical trials to evaluate efti as part of a therapeutic cancer vaccine containing CYTLIMIC's innovative cancer peptide vaccine, called CYT001.

Immutep enters into clinical trial collaboration agreement with Cytlimic

The companies will collaborate on clinical trials to evaluate efti as part of a therapeutic cancer vaccine containing CYTLIMIC's cancer peptide vaccine, called CYT001.

Immutep, CYTLIMIC

Dubai: A top official on Tuesday denied media reports that cervical cancer vaccine will be made mandatory for schoolgirls in Dubai and Northern Emirates.

Cervical cancer vaccine mandatory rumour denied in UAE

Moderna Therapeutics and Merck, known as MSD outside the United States and Canada, have expanded their 2016 collaboration to develop and commercialize novel personalized messenger RNA (mRNA) cancer vaccines to now include shared antigen mRNA cancer vaccines including mRNA- 5671, Moderna's mRNA KRAS cancer vaccine.

MODERNA AND MERCK EXPAND COLLABORATION

M2 EQUITYBITES-May 31, 2018-BlueWillow Biologics wins therapeutic cancer vaccine patent in the US

BlueWillow Biologics wins therapeutic cancer vaccine patent in the US

"Pending replication in humans, our findings indicate these cells may one day serve as a true patient-specific cancer vaccine."

Work on cells could result in cancer vaccine

Johnathan's presentation will be focused on the 'Enhanced Cancer Vaccine Effectiveness With NKTR-214 A CD 122-Biased Cytokine'.

Nektar Therapeutics, Senior Vice President of Biology and Preclinical Development Explores Enhanced Cancer Vaccine Effectiveness

As of now, the cancer vaccine takes months to make and is very costly.

Personalized 'cancer vaccine' clinical trials show positive results